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Abstract
A rise in the prevalence of depression underscores the need for accessible and effective interventions. The objectives of 
this study were to determine if the addition of a treatment component showing promise in treating depression, heart rate 
variability-biofeedback (HRV-B), to our original smartphone-based, 8-week digital intervention was feasible and whether 
patients in the HRV-B (“enhanced”) intervention were more likely to experience clinically significant improvements in 
depressive symptoms than patients in our original (“standard”) intervention. We used a quasi-experimental, non-equivalent 
(matched) groups design to compare changes in symptoms of depression in the enhanced group (n = 48) to historical out-
come data from the standard group (n = 48). Patients in the enhanced group completed a total average of 3.86 h of HRV-B 
practice across 25.8 sessions, and were more likely to report a clinically significant improvement in depressive symptom 
score post-intervention than participants in the standard group, even after adjusting for differences in demographics and 
engagement between groups (adjusted OR 3.44, 95% CI [1.28–9.26], P = .015). Our findings suggest that adding HRV-B to 
an app-based, smartphone-delivered, remote intervention for depression is feasible and may enhance treatment outcomes.
Keywords Depression · Heart rate variability · Biofeedback · Smartphone app · Online intervention · Digital health · 
mHealth · Mindfulness · Meditation
The global burden of depression, the world’s leading cause 
of disability (Geneva: World Health Organization 2017), is 
undeniably large. Increased risk of other comorbid mental 
and physical disorders, decreased functioning, quality of life 
and productivity, and increased risk of early mortality drive 
the yearly $210.5 billion economic burden of depression in 
the U.S. alone (Greenberg et al. 2015). Despite the availabil-
ity of several evidence-based treatments, the prevalence of 
depression has continued to rise—an estimated 18% between 
2005 and 2015 (Kessler 2012; McCall and Kintziger 2013; 
National Council for Behavioral Health 2017). The chronic 
and recurrent nature of depression further underscores the 
critical need for effective, long-lasting interventions that 
those affected can easily access.
Current treatments for depression typically include 
either psychotherapy and/or medication (Huhn et al. 2014), 
which require highly trained professionals to administer. 
When treated with antidepressants, an estimated 30–50% 
of patients do not show significant symptom improvement 
(El-Hage et al. 2013), up to 80% report at least one side 
effect (Wang et al. 2018), and at least 50% of patients are 
likely to relapse within 6- to 12-months of treatment with-
drawal (Baldessarini et al. 2015; Johansson et al. 2015). 
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Shortages in trained providers have brought even more 
attention to the urgent need to provide alternative solu-
tions (National Council for Behavioral Health 2017). Self-
directed therapies that can be easily learned, mastered, and 
utilized by depressed patients might help address some 
of these access issues. Internet- and smartphone-based 
depression treatments delivered with minimal guidance 
have demonstrated clinical effectiveness (Firth et al. 2017; 
Richards and Richardson 2012), with effect sizes similar to 
face-to-face interventions (Carlbring et al. 2018).
As such, we created the Meru Health online digital 
clinic to deliver a comprehensive 8-week intervention to 
patients via a Smartphone app. The program is overseen 
by a remote licensed therapist, who monitors progress via 
data collected in the app and provides feedback as needed. 
Content delivered in the weekly modules is derived from 
several evidence-based treatments for depression including 
Mindfulness-Based Meditation (MM) (Kabat-Zinn 1994; 
Morgan 2003), Cognitive-Behavioral Therapy (CBT) 
(Beck 1979), and Behavioral Activation Therapy (BAT) 
(Jacobson et al. 2001) delivered via texts, videos, and daily 
practices. Analyses of this program have indicated post-
intervention clinically significant reductions in depres-
sive symptoms that remain at 6- and 12-month follow-up 
assessments (Economides et al. 2019; Goldin et al. 2019).
As part of making continuous improvements to the 
Meru Health intervention, we recently added another 
self-directed component to the program—heart rate vari-
ability biofeedback (HRV-B). Heart rate variability (HRV) 
describes the variation in interbeat time intervals among 
heart beats, and is believed to be a marker of the body’s 
ability to self-regulate during times of distress via inter-
actions between the cardiac and emotional control cent-
ers of the body (Sztajzel 2004). Low levels of HRV have 
been found for a number of medical conditions, as well as 
cognitive and mental health problems (Camm et al. 1996; 
Friedman 2007; Thayer and Lane 2009; Thayer and Stern-
berg 2006), including depression (Kemp et al. 2010). As 
such, therapies that increase HRV strengthen various mod-
ulatory reflexes in the cardiovascular system and improve 
emotional regulation, thus providing benefit to those suf-
fering from these conditions (Lehrer and Eddie 2013). One 
such therapy is HRV-B, which involves learning a breath-
ing technique that maximizes HRV while monitoring pro-
gress throughout the training (Gevirtz 2013; Lehrer and 
Gevirtz 2014). Potential mechanisms of therapeutic effect 
involve HRV-B strengthening the parasympathetic system, 
the baroreflex (one of the body’s homeostatic mechanisms 
that helps to maintain a relatively constant blood pressure), 
and/or the inflammation response, such that the body is 
better able to respond to, regulate, and recover from a dis-
tressing event (Lehrer and Gevirtz 2014). Regular practice 
of this technique has thus been proposed to help mitigate 
the stress response when faced with a stressful situation 
(Yu et al. 2018).
Several preliminary studies have reported a therapeutic 
benefit of HRV-B for patients with high levels of anxiety, 
stress, and depression (Blasé et al. 2016; Gevirtz 2013; May 
et al. 2019; Siepmann et al. 2014; van der Zwan et al. 2019). 
Thus, clinicians have begun integrating HRV-B into exist-
ing depressive treatments (Gevirtz 2015). One small trial 
showed that adding HRV-B to psychotherapy improved post-
intervention depressive symptom outcomes significantly 
more than psychotherapy alone (Caldwell and Steffen 2018). 
Based on these promising findings and with the understand-
ing that, to our knowledge, there has not been an investiga-
tion of whether HRV-B can be integrated into a depression 
intervention delivered remotely, we conceived the present 
analysis of our real-world data. Our main objectives were to 
determine (1) if the addition of HRV-B to our mobile health 
depression intervention delivered via a Smartphone app 
(“enhanced program”) is feasible, and (2) whether patients 
in our enhanced program were more likely to experience 
clinically significant improvement in depressive symptoms 
compared with patients in our original (“standard”) program 
with no HRV-B component, after controlling for differences 
in engagement. We hypothesized that the enhanced program 
patients would be able to complete the HRV-B practices and 
engage in our remote program and, compared to patients 
enrolled in the standard program, be more likely to have 
clinically significant improvements in depressive symptoms. 
As a secondary aim, we evaluated whether the degree of 




We used a quasi-experimental, pre- and post-inter-
vention, non-equivalent groups design to compare an 
HRV-B enhanced version of the Meru Health interven-
tion (“enhanced”) to historical outcome data from the 
standard Meru Health intervention (“standard”). For each 
group, symptoms of depression were measured pre-inter-
vention (“baseline”), during weeks 1, 3, 5 and 7 of the 
intervention, and at the end of the 8-week intervention 
(“post-intervention”).
Participants
The present study included adult patients treated at the Meru 
Health online clinic, a national remote healthcare provider 
that currently operates in the US and Finland. The enhanced 
group consisted of 48 participants that took part in the 
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HRV-B enhanced intervention between October 2018 and 
March 2019. Each participant in the enhanced group was 
matched to a single participant that had previously engaged 
with the standard Meru Health intervention (which did not 
include HRV-B). Standard group participants were selected 
from a pool of 76 participants that took part in the Meru 
Health intervention between April 2017 and January 2019. 
We used 1:1 nearest-neighbor matching (using the knnsearch 
function in Matlab® R2016b) without replacement and used 
baseline PHQ-9 score and antidepressant status as covari-
ates, as we conjectured these would have the largest impact 
on depression symptoms over time. This resulted in 48 par-
ticipants in the standard group that took part in the interven-
tion between October 2017 and January 2019 selected for 
analysis.
Participants were recruited via online Facebook adver-
tisements that sought individuals for a smartphone-based 
intervention (SBI) for depression that included self-guided 
smartphone-delivered content, private access to a thera-
pist via messaging, and an anonymous group chat feature 
amongst participants. Importantly, the method of recruit-
ment and messaging of the advertisements was identical for 
both groups. Participants were given free access to the app 
and trained on how to use the anonymous group chat feature, 
as well as how to communicate with their assigned therapist, 
prior to beginning the intervention. Participant demograph-
ics (age, gender, and antidepressant status) were acquired 
prior to the intervention via an intake questionnaire admin-
istered online. Outcome measures were administered via the 
Meru Health smartphone app, except for baseline measures 
which were acquired during screening. Since there is a varia-
ble delay between screening and the start of the intervention, 
baseline scores are completed up to a maximum of 30 days 
prior to the intervention start date. Post-intervention scores 
were considered valid if reported during or within 2 weeks 
following the intervention end-date.
For inclusion, participants had to provide informed con-
sent via the Meru Health app, own a smartphone, have at 
least moderate symptoms of depression (a score ≥ 10 on 
the Patient Health Questionnaire [PHQ-9] at baseline), and 
acknowledge/demonstrate the ability to commit to a mini-
mum of 20 min of practice per day, for 6 days per week, 
across the 8-week intervention (as judged by both the par-
ticipant and their assigned therapist). Exclusion criteria 
included a previous suicide attempt, severe active suicidal 
ideation with a specific plan, severe self-harm, active sub-
stance abuse, or a history of psychosis. Inclusion/exclusion 
criteria were assessed prior to enrolment via phone-based 
screening interviews between study participants and inter-
vention therapists, as per the standard treatment procedure 
at the online clinic. Participants were not compensated for 
their time but could participate in the intervention for free. 
Data were collected as part of the standard Meru Health 
intervention, and all procedures used were reviewed by Pearl 
IRB, who granted institutional review board exemption for 
analyses of previously collected and de-identified data, 
deemed as having been performed in accordance with the 
1964 Helsinki declaration and its later amendments or com-
parable ethical standards. All participants provided informed 
consent for their anonymized data to be used for research 
purposes prior to participation.
Intervention
Standard Intervention
The standard Meru Health intervention has been described 
in detail previously (Economides et al. 2019; Goldin et al. 
2019). Briefly, the intervention consists of 8 modules deliv-
ered sequentially over an 8-week period, that include con-
tent derived from evidence-based practices such as Mindful-
ness-Based Stress Reduction (MBSR) (Kabat-Zinn 1994), 
Mindfulness-Based Cognitive Therapy (MBCT) (Morgan 
2003), Cognitive-Behavioral Therapy (CBT) (Beck 1979), 
and Behavioral Activation Therapy (BAT) (Jacobson et al. 
2001). The content includes text, video, audio-guided mind-
fulness meditation (MM) exercises, infographics that illus-
trate CBT principles, and journal prompts. Daily content and 
practices range from 10 to 30 min, except for the first day of 
each week, in which a series of introductory videos extend 
the content to a maximum of 45 min. The intervention also 
includes anonymous peer support via a group discussion 
board, and support by a licensed Meru Health-employed 
remote therapist. Therapists review participant engagement 
and self-reported outcomes throughout the intervention and 
provide 1:1 support to participants via messaging (and less 
frequently, phone calls). Participants can also message thera-
pists directly when needed.
Enhanced Intervention
The enhanced intervention consists of the same core mod-
ules, structure and content as the standard intervention, with 
the addition of daily HRV-B exercises, referred to as “reso-
nance breathing” within the Meru Health app (see Fig. 1). 
These exercises start at a duration of 5 min and gradually 
increase up to a maximum of 20 min from week 4 of the 
intervention onwards (though participants could adjust the 
duration in 5-min increments according to their preference). 
To accommodate the HRV-B exercises, the enhanced inter-
vention features 2 h and 56 min less MM content than the 
standard intervention (though in practice this difference can 
vary according to the number of days in which participants 
engage with the intervention, and whether any MM sessions 
are completed more than once).
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Participants self-administered HRV-B via the Meru 
Health app using a HeartMath® Bluetooth photoplethys-
mography (PPG) sensor, which was sent to each participant 
prior to starting the intervention. The sensor collected data 
either from an earlobe or from a fingertip. Each participant 
received a brief written introduction to HRV and resonance 
breathing, including how to use the sensor, and was required 
to complete introductory content via the Meru Health app, 
during which they could set a daily time / reminder to engage 
with the practice. During each HRV-B session, participants 
were guided by a visual pacer that expands during inhala-
tion for 4 s and contracts during exhalation for 6 s, achieving 
resonance breathing at rate of approximately 6 breaths per 
minute. The visual pacer was supplemented with recorded 
breaths that matched the rate of the visual pacer. Below the 
pacer, participants were shown a real-time visual trace of 
their heart rate which appeared green during periods of high 
resonance and amber during low resonance (see Fig. 1a). 
Participants had the option of enabling or disabling both 
the recorded breaths and the heart rate trace (by tapping the 
smartphone screen). At the end of the practice participants 
were shown summary feedback detailing the session dura-
tion and time spent in high and low resonance.
The first session of the intervention featured additional 
audio-based instructions that guided participants through 
the session. Participants were instructed to sit comfortably, 
relaxing their face, neck and shoulders, and to take slow, 
comfortable breaths in sync with the visual pacer. After 
settling into a comfortable breathing rhythm, participants 
were instructed to pay attention to the heart rate trace and 
attempt to stay in the green (high resonance) zone. Partici-
pants were re-assured that achieving high resonance takes 
practice, that it was okay to take breaks if they began to 
experience feelings of frustration, and that they should focus 
on breathing in and out fully until they were ready to re-
focus on the tracer. The instructions also featured a brief 
explanation of the relationship between heart rate, breathing, 
and the body’s ability to self-regulate.
Patient‑Reported Outcomes
The primary outcome was clinically significant improvement 
in depression (response rate) from pre- to post-intervention, 
analyzed as a binary variable for which improvement was 
defined as ≥ 50% reduction in PHQ-9 score combined with a 
post-intervention score < 10 (Kroenke et al. 2001). We chose 
to analyze clinically significant improvement as a binary 
variable as we conjectured this would be most relevant to cli-
nicians and patients, and this approach has been widely used 
in clinical trials for depression (Cipriani et al. 2018; Cuijpers 
et al. 2010; Kessler et al. 2009; Moleiro and Beutler 2009). 
We also analyzed PHQ-9 scores as a continuous variable, 
and report average (mean and median) change in PHQ-9 
scores for each group at each time-point as a secondary 
outcome.
Fig. 1  Screenshots of the Meru Health application. The screenshots 
depict HRV-B practice in the enhanced group (a), daily practices 
common to both groups (b), and messaging between patient and ther-
apist (c). The colored heart rate tracer in the HRV-B practice (bottom 
of panel a) displays amber during period of low resonance and green 
during periods of high resonance
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Engagement Metrics
For participants in each group, we report: the number of 
complete MMs, CBT/BAT exercises, and videos viewed 
(including introductions to each week of the intervention 
and other psychoeducational videos); the total volume of 
MM practice (in hours); the total number of messages sent 
by participants to their therapist, and the total number of 
messages received by participants from their therapist. For 
participants in the enhanced intervention we also report: the 
total number of complete HRV-B practices, the total duration 
(in hours) of HRV-B practice, and the average number and 
duration of HRV-B practices per week of the intervention.
Statistical Analysis
Descriptive statistics were calculated for participant demo-
graphics, engagement metrics, and attrition rate in each 
group. For each participant, we calculated two summary 
measures of intervention engagement. The first involved 
summing the total number of complete app-based exer-
cises common to both groups (including MM, CBT, and 
BAT exercises), known as “total complete exercises”. The 
second involved summing the total volume of meditation 
for participants in the standard group, and total combined 
volume of meditation and HRV-B practice for participants in 
the enhanced group, known as “total duration of practice”. 
We used repeated-measures ANOVA with Huynh–Feldt 
adjustment to examine changes in HRV-B practice over time 
for participants in the enhanced group. Outcome measures 
were analyzed using an intention-to-treat (ITT) approach 
in which all participants were included, regardless of inter-
vention engagement or attrition (though we excluded n = 2 
participants who did not start the intervention and who did 
not complete a baseline PHQ-9 measure).
For the primary outcome, we used logistic regression 
to compare the binary outcome of clinically significant 
improvement in PHQ-9 at post-intervention (coded as 1 
for improvement, 0 for no improvement) between groups 
(coded as 1 for enhanced, 0 for standard). We used both 
simple logistic regression and multivariate logistic regres-
sion controlling for the following covariates: (i) baseline 
PHQ-9 score, (ii) age, (iii) gender, (iv) antidepressant status 
(coded as 1 for yes, 0 for no), (v) total complete exercises 
(as defined above), (vi) total duration of practice (as defined 
above), (vii) the number of messages sent by participants to 
their therapist, and (viii) the number of messages received 
by participants from their therapist. Since there was a high 
degree of colinearity between total complete exercises and 
total volume of practice, we repeated the regression includ-
ing either metric alone, or both together, which produced 
equivalent results with regards to the effect of group. Since 
we were interested in the relationship between program 
engagement and symptom improvement, we report the coef-
ficient and p-value associated with total complete exercises 
and total volume of practice whilst including either one or 
the other in the model. We used last observation carried 
forward (LOCF) to impute missing post-intervention PHQ-9 
scores. We report the odds ratio (OR) and adjusted OR, 
95% CI, and P-value associated with clinically significant 
improvement in the enhanced group relative to the standard 
group. We also report any covariates that were significant 
predictors of clinically significant improvement at the 5% 
significance level. Finally, we report the number needed to 
treat (NNT) for the enhanced relative to the standard group 
with 95% CIs calculated using Eqs. 1 and 2 from Bender 
(2001).
For the secondary continuous PHQ-9 outcome, we used 
linear mixed effects modelling (LMM) via the “lme4” pack-
age in R, with “time” (coded as 0, 1, 3, 5, 7, and 9), “group” 
(enhanced or standard), and their interaction included as 
fixed effects, and a separate baseline for each participant 
(random-intercept model). We ran the model whilst treating 
time as linear or as a categorical variable, and report both 
results. We controlled for the same covariates as in the multi-
variate logistic regression above, with the addition of 2-way 
interaction terms between “time” and covariates (iv) to (vii). 
We repeated the analysis by both allowing the mixed effects 
model to account for missing data and by using LOCF to 
impute missing values, which produced equivalent results. 
We report the contrast estimate, 95% CI, and P-value for 
each fixed effect. The estimated marginal mean (EMM) and 
standard error for each time-point and each group was cal-
culated using the “emmeans” package in R. We also report 
PHQ-9 scores according to a per protocol analysis in which 
only participants with complete scores were included.
We ran several exploratory analyses to investigate the 
relationship between participant demographics and attri-
tion/engagement, and the relationship between volume of 
HRV-B practice and change in PHQ-9 scores. For the former 
we used multivariate logistic regression with attrition as the 
dependent variable (where 1 and 0 indicated the presence or 
absence of a post-intervention PHQ-9 score, respectively). 
We also used multiple linear regression with total complete 
exercises, or total duration of practice as the dependent vari-
able. In each case the explanatory variables included base-
line PHQ-9 score, age, gender, antidepressant status, and 
group (enhanced or standard).
For the latter, using data from the enhanced group only, 
we used multiple linear regression and multivariate logis-
tic regression to test whether total HRV-B engagement (in 
hours) predicted PHQ-9 score change or the presence of a 
clinically significant reduction in PHQ-9 score, respectively, 
whilst controlling for all covariates listed in the primary 
outcome analysis. Since volume of HRV-B practice was 
correlated with other engagement metrics, we repeated the 
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analysis with and without including total complete exercises 
and total volume of meditation as covariates, and report both 
results.
Sample Size
Since the present study used existing real-world data from 
the Meru Health online clinic, an a priori power calculation 
was not applicable. We conducted a post-hoc power cal-
culation for the primary outcome which suggested that we 
achieved 0.79 power with a total sample size of n = 96 and 
an adjusted OR of 3.44 at an alpha level of 0.05 (two-tailed).
Effect Size Calculation
We computed a Cohen’s d effect size and 95% CI for the 
primary outcome by converting the odds ratio using Eqs. 15 
and 17 from Sánchez-Meca et al. (2003).
Results
Participants and Program Adherence
Participant demographics are presented in Table 1. The 
majority of participants were based in Finland (90.6%) 
and approximately one-third were taking an antidepres-
sant prior to enrollment. Average PHQ-9 scores at baseline 
were similar between groups (two-sample t-test, P = 0.58), 
and at the boundary between moderate and moderately-
severe depression (mean = 15.2, SD 3.69). On average, 
relative to the standard group, participants in the enhanced 
group were marginally but significantly older (mean dif-
ference = 2.9  years; two-sample t-test, P = 0.03), and 
comprised a slightly lower proportion of males and those 
taking antidepressant medication. However, differences 
in gender (χ2 = 3.35, P = 0.07), antidepressant status 
(χ2 = 0.74, P = 0.39), and country (χ2 = 0, P = 1) were not 
significantly different between groups.
The number of participants with a complete post-inter-
vention PHQ-9 score was 40 (83.3%) in the enhanced 
group and 35 (72.9%) in the standard group (χ2 = 0.98, 
P = 0.32). Participants with higher PHQ-9 scores at base-
line were less likely to have a complete post-intervention 
PHQ-9 score (b = − 0.16, P = 0.041). No other covariates 
were predictive of attrition.
Intervention Engagement
Summary engagement metrics for each group are shown 
in Table 2. Across the 8-week intervention, participants 
completed an average of 34.5 meditations totaling 7.82 h, 
viewed 17.7 videos (including introductions to each week 
of the intervention and other psychoeducational videos), 
and completed 29.6 CBT/BAT exercises. Participants also 
sent approximately 20 messages (across 12 separate days) 
to their therapist and received approximately 46 mes-
sages (across 25 separate days) from their therapist. Rela-
tive to the standard group, participants in the enhanced 
group completed more CBT/BAT exercises (t(94) = 2.59, 
P = 0.01) and more psychoeducational videos (t(94) = 2.80, 
P = 0.01), but spent less time meditating (mean differ-
ence = 2.33 h, t(94) = − 1.61, P = 0.11), though the latter 
did not reach statistical significance (likely due to sub-
stantial individual variation in hours spent meditating; 
range = 0—29.2 h). In addition, females were likely to 
complete a higher total number of intervention practices 
(including CBT/BAT, MM, and psychoeducational vid-
eos [b = 30.8, P = 0.013]), and engage in a higher total 
duration of meditation practice (b = 3.93, P = 0.017), than 
males.
Table 1  Participant 
demographics
PHQ Patient Health Questionnaire, SD standard deviation, US United States
All participants 
(n = 96)
Enhanced (n = 48) Standard (n = 48)
Baseline PHQ-9 (mean, SD) 15.3 (3.69) 15.5 (3.68) 15.1 (3.73)
Age (mean, SD) 34.3 (6.51) 35.8 (6.34) 32.9 (6.41)
Gender
Female (n, %) 78 (81.3) 43 (89.6) 35 (72.9)
Male (n, %) 18 (18.7) 5 (10.4) 13 (27.1)
Antidepressants
Yes (n, %) 33 (34.4) 14 (29.2) 19 (39.6)
No (n, %) 63 (65.6) 34 (70.8) 29 (60.4)
Country
Finland (n, %) 87 (90.6) 43 (89.6) 44 (91.7)
US (n, %) 9 (9.4) 5 (10.2) 4 (8.3)
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HRV‑B Engagement
Participants in the enhanced group completed a total aver-
age of 3.86 h of HRV-B practice across 25.8 sessions. Both 
the number of sessions completed (F(7,329) = 31.4, P < 0.001) 
and the average number of minutes of HRV-B practice 
(F(7,329) = 8.34, P < 0.001) decreased across the intervention 
(see Table 3). However, the mean duration of each HRV-B 
session completed increased from approximately 6 min to 
11 min, consistent with the structure of the intervention.
Patient‑Reported Outcomes
In an ITT analysis, simple logistic regression revealed 
that participants in the enhanced group were more likely 
to report a clinically significant improvement in PHQ-9 
score post-intervention than participants in the standard 
group (56.3% versus 29.2%; OR 3.12, 95% CI [1.34–7.26], 
P = 0.013). This effect remained robust when using multivar-
iate logistic regression to adjust for participant demograph-
ics and differences in engagement between groups (adjusted 
OR = 3.44, 95% CI [1.28–9.26], P = 0.015). The difference 
in proportions reaching clinically significant improvement in 
PHQ-9 symptoms yielded a number needed to treat (NNT) 
of 4 (95% CI [2 to 12]) and a Cohen’s d effect size of 0.63 
(95% CI [0.16 to 1.09]). In addition, participants not tak-
ing antidepressants (b = − 1.18, P = 0.031), and those who 
completed more intervention exercises (“total complete exer-
cises”, b = 0.02, P = 0.024) were more likely to report a clini-
cally significant improvement in PHQ-9. A similar pattern 
Table 2  Participant engagement
SEM standard error of the mean
All participant (n = 96) Enhanced (n = 48) Standard (n = 48)
No. of complete meditations
 Mean (SEM) 34.5 (2.71) 34.3 (3.66) 34.7 (4.02)
 Min–max 0–143 1–133 0–143
Total meditation hours
 Mean (SEM) 7.82 (0.62) 6.84 (0.74) 8.81 (0.97)
 Min–max 0–29.2 0–26.3 0.28–29.2
No. of complete CBT/BAT exercises
 Mean (SEM) 29.6 (1.77) 34.0 (2.43) 25.1 (2.44)
 Min–max 0–78 0–78 0–56
No. of complete psychoeducation videos
 Mean 17.7 (0.61) 19.4 (0.72) 16.1 (0.93)
 Min–max 3–27 4–27 3–25
No. of messages sent
to therapist
 Mean (SEM) 19.9 (1.87) 21.7 (2.71) 18.1 (2.57)
 Min–max 0–99 0–99 0–71
No. of messages received from therapist
 Mean (SEM) 46.8 (2.47) 47.7 (3.69) 46.0 (3.32)
 Min–max 0–132 0–132 5–101
Total HRV-B hours
 Mean (SEM) n/a 3.86 (0.47) n/a
 Min–max n/a 0–13 n/a
Table 3  HRV-B engagement
SEM standard error of the mean
Week
1 2 3 4 5 6 7 8
Minutes of practice, mean (SEM) 34.6 (2.85) 30.2 (3.39) 39.2 (4.13) 31.6 (4.86) 31.9 (4.33) 20.2 (3.64) 20.6 (3.93) 23.6 (5.56)
No. of complete sessions, mean (SEM) 5.67 (0.40) 4.27 (0.40) 3.98 (0.39) 3.10 (0.45) 2.79 (0.35) 1.81 (0.33) 2.02 (0.35) 2.10 (0.48)
Duration per session in minutes, mean 
(SEM)
5.92 (0.17) 6.78 (0.33) 9.64 (0.40) 9.93 (0.57) 11.1 (0.40) 11.4 (0.60) 10.1 (0.56) 11.2 (0.60)
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emerged if we included total duration of practice instead of 
total complete exercises in the model (see Methods; b = 0.07, 
P = 0.055).
Linear mixed effects modelling of PHQ-9 scores revealed 
a significant main effect of time (b = − 0.81, 95% CI [− 1.16 
to −  0.46], P < 0.001) and a group x time interaction 
(b = − 0.22, 95% CI [− 0.44 to − 0.01], P = 0.043), suggest-
ing that on average participants in the enhanced group expe-
rienced larger reductions in PHQ-9 scores over time than the 
standard group. When using the more conservative approach 
of treating ‘time’ as categorical (and thus not assuming a 
linear trend), PHQ-9 was only significantly different between 
groups at week 5 (mean difference = 2.20, 95% CI 0.41 to 
3.99, P = 0.018) of the intervention (see Table 4; also see 
Fig. S1 for pre-post change in PHQ-9 across individual 
participants).
HRV‑B Engagement And Patient‑Reported 
Outcomes
Within the enhanced group, participants who completed a 
higher total volume of HRV-B practice were likely to expe-
rience larger reductions in PHQ-9 symptoms (b = 0.68, 
P = 0.037). This remained marginally significant when con-
trolling for engagement with other intervention practices, 
despite an increase in multicollinearity (b = 0.64, P = 0.053). 
However, HRV-B engagement did not predict the likelihood 
of clinically significant improvement when analyzing PHQ-9 
change as a binary outcome (b = 0.2, P = 0.16).
Discussion
The present study evaluated the feasibility and impact of 
incorporating HRV-B training into a smartphone-based, 
remotely-delivered, psychological intervention (Meru 
Health) for depression. We sought to determine if the 
enhanced intervention (including HRV-B) was associated 
with a higher probability of clinically significant improve-
ment in depression relative to delivering the intervention 
without HRV-B. Using historical outcome data from the 
standard intervention as a comparison group, the present 
results suggest that adding HRV-B to the intervention 
is both feasible and associated with improved treatment 
outcomes.
HRV-B has seen a recent increase in popularity and has 
shown promise in effectuating improved outcomes across a 
range of disorders (Blase et al. 2016; Gevirtz 2013). How-
ever, to our knowledge this is the first demonstration of 
HRV-B being delivered remotely as an adjunct to a smart-
phone-based intervention for depression. A major benefit 
of app-based interventions is the ability to track participant 
engagement objectively. Here, participants with elevated 
symptoms of depression were able to complete a total of 
almost 4 h of HRV-B practice across 26 sessions, suggesting 
that the addition of HRV-B is both feasible and acceptable.
Although participants were able to increase the duration 
of each HRV-B session over time, the frequency (and thus 
overall volume of HRV-B practice) decreased across inter-
vention weeks. This is consistent with previous reports that 
participants meditate less frequency over the course of the 
intervention (Goldin et al. 2019) and suggests that decreases 
in engagement are not specific to individual components of 
the intervention. Such global decreases in engagement may 
stem from fatigue, boredom, or a reduction in motivation. 
One of the authors (RG) has observed better adherence to 
daily HRV-B practice when in-session feedback included 
elements of gamification that rewarded participants for 
achieving optimal resonance. Future research should focus 
on understanding obstacles to HRV-B engagement, modify-
ing the intervention to account for such obstacles, and devel-
oping methods to support sustained HRV-B practice.
Table 4  Secondary patient-reported outcome means (SEM)
PP per protocol, ITT intent to treat, SEM standard error of the mean, w week
Time-point
Baseline w1 w3 w5 w7 Post
Standard group
 ITT mean 15.41 (0.63) 15.04 (0.64) 12.31 (0.70) 11.66 (0.71) 10.41 (0.71) 8.81 (0.70)
 ITT median 15 14 11 12 10.5 10
 PP mean 15.08 (0.68) 14.47 (0.81) 12.00 (0.77) 11.00 (0.78) 10.00 (0.96) 8.37 (0.99)
 PP median 15 14 11 10 8.5 8
Enhanced group
 ITT mean 16.57 (0.71) 15.09 (0.71)15.09 (0.71) 12.24 (0.72) 10.61* (0.72) 10.09 (0.74) 9.16 (0.74)
 ITT median 15 13 11 9 9 7
 PP mean 15.50 (0.62) 13.98 (0.63) 11.22 (0.79) 9.23 (0.67) 8.80 (0.68)(0.68) 7.85 (0.76)
 PP median 15 13 11 8 9 6
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Participants in the enhanced HRV-B group completed 
fewer meditations than participants in the standard group, 
which is consistent with the adapted structure of the 
enhanced intervention. However, HRV-B participants also 
engaged with significantly more CBT/BAT exercises, and 
more weekly introduction videos than those in the stand-
ard group. This higher pattern of engagement was unex-
pected and deserves additional investigation. One possibil-
ity is that the increase in intervention components in the 
enhanced HRV-B group helped to maintain participants’ 
attention and reduce fatigue. However, it’s also plausible 
that the increase in engagement was due to factors outside of 
the research group’s control, and further work is needed to 
establish whether higher engagement in the enhanced group 
remains robust in larger samples and under more controlled 
conditions.
The finding that participants in the enhanced group were 
more likely to experience clinically significant improvements 
in PHQ-9 compared to the standard group is consistent with 
other preliminary evidence that HRV-B is an effective means 
to reduce symptoms of depression (Karavidas et al. 2007; 
Patron et al. 2012; Rene et al. 2011; Siepmann et al. 2008; 
Steffen et al. 2017; Zucker et al. 2009). In particular, one 
recent study reported decreases in depression following a 
6-week HRV-B intervention for participants with major 
depression (Lin et al. 2019), whilst another reported that 
combining psychotherapy with HRV-B was more effective 
in reducing symptoms of depression over a 6-week period 
than psychotherapy alone (Caldwell and Steffen 2018). The 
present study suggests that combining HRV-B with other 
evidence-based psychological treatments for depression 
may improve treatment outcomes, even when treatment is 
delivered remotely. This is particularly promising given that 
the standard Meru Health intervention (without HRV-B) has 
already been associated with clinically significant reductions 
in symptoms of depression that persist for at least one-year 
post-intervention (Economides et al. 2019; Goldin et al. 
2019). Although the present study was not a randomized 
trial, and we thus cannot be sure that the difference between 
groups was causally related to HRV-B, the fact that partici-
pants who engaged with a higher volume of HRV-B practice 
were also likely to experience larger reductions in depres-
sion symptoms lends further support to the idea that HRV-B 
may be an effective component of depression treatment. 
These findings underscore the need for additional studies of 
HRV-B in randomized controlled settings to better under-
stand its efficacy and to explore the mechanisms responsible 
for its impact on symptoms of depression.
Whilst the enhanced intervention was associated with 
higher odds of clinically significant improvement than the 
standard group, differences in the average (mean) reduc-
tion in PHQ-9 scores between groups was less clear. Since 
a proportion of participants reported extreme score changes, 
and the sample size in the present study was modest, mean 
changes in score might mask underlying differences between 
intervention groups. In particular, one participant in the 
enhanced group reported an extreme worsening of symp-
toms, whilst three participants in the standard group reported 
an extreme improvement in symptoms (see Fig. S1). Indeed, 
when using median values the difference in pre-post score-
change between groups was more evident. However, we 
caution the reader not to overinterpret the present results. 
Although our study suggests that the enhanced intervention 
was more consistently associated with clinically significant 
improvements in depression than the standard intervention, 
further work is needed to understand whether there is an 
overall difference in efficacy between groups at both post-
intervention and into the future. Presumably, HRV-B is a 
skill that, once mastered, can become routine. Given the 
high likelihood of relapse of depression, additional stud-
ies are needed to investigate the impact of HRV-B on such 
long-term outcomes.
Exploratory analyses revealed a number of results worth 
considering. First, participants who reported taking antide-
pressants at the start of the intervention were less likely to 
experience clinically significant improvements (regardless 
of intervention group), even after accounting for baseline 
differences in symptom severity. This is surprising given 
evidence that psychotherapy combined with pharmacother-
apy is somewhat more effective than psychotherapy alone at 
relieving symptoms in the short-term (Cuijpers et al. 2015). 
One possibility is that participants taking antidepressants 
may have been more likely to be experiencing recurrent or 
persistent symptoms of depression (rather than having a 
first-depressive episode), and thus less susceptible to treat-
ment. However, given a modest sample size and limited 
information on the type and timeframe of antidepressant 
usage, further work is needed in order to expand upon this 
finding. Moreover, although gender was not predictive of 
symptom reduction associated with the intervention, female 
engagement was higher across the intervention than male 
engagement. Whilst males are less likely than females to 
seek help for depression (Galdas et al. 2005; Kessler et al. 
2005), there is little evidence to suggest that males enrolled 
in online interventions will engage less. Given that just 19% 
of the participants in the present study were male, further 
research is needed to understand any gender-based differ-
ences in the delivery and/or outcomes associated with the 
Meru Health intervention.
Limitations
Our promising findings should be interpreted in light 
of several limitations. We used a non-equivalent groups 
design comparing an enhanced version of the Meru Heart 
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intervention to historical outcome data from the standard 
intervention. Thus, participants were not randomly allocated, 
the researchers were not blinded to group, and we did not 
include a conventional control group. Despite attempting to 
match participants across important attributes and adjust for 
potential confounders in our regression models, we cannot 
exclude the possibility that our results were driven by differ-
ences between groups at baseline, and not by the addition of 
HRV-B to the enhanced intervention.
Similarly, engagement with intervention practices com-
mon to both groups (such as CBT and BAT components) 
was higher in the enhanced group than the standard group, 
which may have driven the difference in treatment outcomes 
between groups. However, our results remained robust when 
controlling for both participant demographics and interven-
tion engagement across all analyses. Moreover, participants 
who engaged with HRV-B the most experienced the largest 
improvement in symptoms, suggesting that HRV-B may have 
played an active role in treatment outcomes.
Further, although engagement with HRV-B was gener-
ally high, we did not assess the extent to which participants 
were able to modulate their heart rate, or breath at resonance 
frequency during HRV-B. In addition, we did not examine 
whether participants in the enhanced intervention experi-
enced increases in HRV across the intervention, or whether 
any such increase was related to symptom reduction. This 
is important because current treatments for depression do 
not resolve lowered HRV, even after successful treatment 
of depressive symptoms (Kemp et al. 2010). Future studies 
designed to investigate these questions are essential if we 
are to fully understand the mechanisms and efficacy of the 
enhanced intervention in treating symptoms of depression.
Lastly, the present study included self-selected partici-
pants who may have been more motivated to engage with the 
intervention than average. Also, the majority of participants 
were female, whilst male participants were found to engage 
with the intervention less frequently. Future studies should 
use more varied recruitment strategies to ensure that the 
present results generalize to larger and more diverse study 
samples.
Conclusions
In conclusion, our findings suggest that adding HRV-B to 
an app-based, smartphone-delivered remote digital interven-
tion for depression is both feasible and effective in reducing 
depressive symptoms. Given the public health burden of 
depression and potential to address access issues plaguing 
many who suffer from depression, the remote application of 
HRV-B for depression treatment is highly promising.
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